Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Indazole derivatives for use in the treatment of influenza virus infection
US9326987B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9326987-B2 |
| Application number | US-201113821594-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 6, 2011 |
| Priority date | Sep 8, 2010 |
| Publication date | May 3, 2016 |
| Grant date | May 3, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of ameliorating symptoms of influenza virus infection comprising administering a safe and effective amount of the compound N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide; or a pharmaceutically acceptable salt thereof. 2. A method of ameliorating symptoms of influenza virus infection comprising administering a safe and effective amount of the compound 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole; or a pharmaceutically acceptable salt thereof. 3. A method of ameliorating symptoms of influenza virus infection comprising administering a safe and effective amount of the compound 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate.
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings · CPC title
spiro-condensed or forming part of bridged ring systems · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Oxadiazoles · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9326987B2 cover?
- The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.
- Who is the assignee on this patent?
- Hamblin Julie Nicole, Jones Paul Spencer, Keeling Suzanne Elaine, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).